UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 16, 2023

 

Lantern Pharma Inc.

(Exact name of registrant as specified in its charter)

 

Delaware		001-39318		46-3973463
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

 

1920 McKinney Avenue, 7th Floor Dallas, Texas		75201
(Address of Principal Executive Offices)		(Zip Code)

 

(972) 277-1136

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: Common Stock

 

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value		LTRN		The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ On June 16, 2023, Lantern Pharma Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders, for the purposes of:

 

 

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

 

 

●

Electing six directors, each to serve until our 2024 Annual Meeting of Stockholders;

 

●

Approving an amendment to the Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan (the “Equity Incentive Plan”) to increase the number of shares of the Company’s common stock available for issuance under the Equity Incentive Plan by an additional 250,000 shares; and

 

●

Ratifying the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.

 

Election of Directors:

 

All of the persons nominated to serve on our board of directors, namely Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Franklyn Prendergast, and David S. Silberstein, were elected to our board of directors, with shares voted as follows:

 

Name		For				Withheld				Broker Non-Vote
Donald Jeff Keyser			3,812,521				443,977				2,805,241
Panna Sharma			4,064,225				192,273				2,805,241
Vijay Chandru			3,810,172				446,326				2,805,241
Maria Maccecchini			3,811,686				444,812				2,805,241
Franklyn Prendergast			4,048,745				207,753				2,805,241
David S. Silberstein			4,060,996				195,502				2,805,241

 

Amendment to Equity Incentive Plan:

 

Our stockholders approved an amendment to the Equity Incentive Plan to increase the number of shares of the Company’s common stock available for issuance under the Equity Incentive Plan by an additional 250,000 shares, with shares voted as follows:

 

For			4,145,520
Against			96,840
Abstain			14,138
Broker Non-Votes			2,805,241

 

Ratification of Independent Registered Public Accounting Firm:

 

In addition, our stockholders ratified the appointment of EisnerAmper LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023, with shares voted as follows:

 

For			7,015,460
Against			41,115
Abstain			5,164

 

There were no broker non-votes on the ratification of our independent registered public accounting firm.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	Lantern Pharma Inc.,
	A Delaware Corporation
Dated: June 21, 2023	By:	/s/ David R. Margrave
		David R. Margrave Chief Financial Officer